TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03988660

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating fibrocytes
Description: Peripheral blood samples were taken from the patients presented with right iliac fossa pain. Samples were collected in sodium heparin (EDTA). Circulating fibrocyte levels were determined by dual staining peripheral blood samples for CD4 and Col-1 using Fluorescence-Activated Cell Sorting (FACS) and correlated with histopathological diagnosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating fibrocytes
Description: Peripheral blood samples were taken from the patients presented with right iliac fossa pain. Samples were collected in sodium heparin (EDTA). Circulating fibrocyte levels were determined by dual staining peripheral blood samples for CD4 and Col-1 using Fluorescence-Activated Cell Sorting (FACS) and correlated with histopathological diagnosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating fibrocytes
Description: Peripheral blood samples were taken from the patients presented with right iliac fossa pain. Samples were collected in sodium heparin (EDTA). Circulating fibrocyte levels were determined by dual staining peripheral blood samples for CD4 and Col-1 using Fluorescence-Activated Cell Sorting (FACS) and correlated with histopathological diagnosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating fibrocytes
Description: Peripheral blood samples were taken from the patients presented with right iliac fossa pain. Samples were collected in sodium heparin (EDTA). Circulating fibrocyte levels were determined by dual staining peripheral blood samples for CD4 and Col-1 using Fluorescence-Activated Cell Sorting (FACS) and correlated with histopathological diagnosis.
Study: NCT04573270

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PrimePro
Description: Intravenous Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PrimePro
Description: Intravenous Injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Injection
Study: NCT06018012

Intervention type: DEVICE
Intervention: MRS and ABR
Description: Magnetic Resonance Spectroscopy and Auditory Brain- stem Response Audiometry

Intervention type: DEVICE
Intervention: MRS and ABR
Description: Magnetic Resonance Spectroscopy and Auditory Brain- stem Response Audiometry

Intervention type: DEVICE
Intervention: MRS and ABR
Description: Magnetic Resonance Spectroscopy and Auditory Brain- stem Response Audiometry
Study: NCT03332537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized IBS Pain SM
Study: NCT04675892

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A1 pulley division
Description: Local anesthesia with 5-10 ml of solution required (90 % lidocaine 1 % with 1 ug epinephrine, 10 % sodium bicarbonate 8.4 %).~Division of the A1 pulley.~Wound closure with absorbable sutures and application of a light dressing.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A1 pulley division + Resection of one or both slips of the FDS tendon
Description: Local anesthesia with 5-10 ml of solution required (90 % lidocaine 1 % with 1 ug epinephrine, 10 % sodium bicarbonate 8.4 %).~Division of the A1 pulley.~Palmar Bruner incision over the PIP joint. Distal dissection and resection of one or both slips of the FDS tendon.~Wound closure with absorbable sutures and application of a light dressing.
Study: NCT02668003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: The CBT intervention, delivered by telephone, will consist of an initial assessment, 6 weekly sessions, and then booster sessions at 3 and 6 months. The intervention will be delivered by trained and accredited therapists. Participants will be supported by a self-management CBT manual. There will be a patient-centred assessment by the therapist for problem identification, risk assessment and development of a shared formulation of the current health problem. The sessions will involve education about musculoskeletal pain, somatic symptoms and specific CBT techniques such as pacing of activity, behavioural activation, diary keeping, identifying and challenging negative and unhelpful thinking patterns and the development of a longer term management plan.
Study: NCT02678819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital cognitive aid
Description: Digital cognitive aid during anesthesia and intensive care crises.
Study: NCT03893786

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Rehabilitation
Description: Fifteen patients with Parkinson's Disease will perform ten 45-minute training sessions of the upper limb bilaterally with the Armeo®Spring, an electromedicad device aimed at improving force and coordination in neurologically affected patients.~The device was built to sustain the forearm during the upperlimb training and is equipped with a VR screen with which the patient may interact during the playful and motivating rehab.
Study: NCT00093847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-adenosyl methione (SAMe)
Description: Oral SAMe tosylate, up to 1600 mg per day for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be taken daily for 6 weeks
Study: NCT02742454

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard 30-60 Seconds Cord Clamping
Description: The infant is stimulated to breathe after birth. If the infant is not breathing well, the cord is clamped at 30 seconds. If the baby is breathing well, the cord is clamped at 60 seconds. Ventilatory assistance is given after cord clamping.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VentFirst 120 Seconds Cord Clamping
Description: The infant is stimulated to breathe after birth. If the infant is not breathing well, PPV by face mask is given starting at 30 seconds. If the baby is breathing well, CPAP is given starting at 30 seconds. The cord is clamped at 120 seconds.
Study: NCT02719938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialty Palliative Care
Description: Specialty inter-disciplinary Palliative Care consultation during hospitalization with post-discharge collaborative care by a Palliative Care Nurse Practitioner and outpatient primary care physician. Clinical care will be augmented by evidence-based educational materials for dementia caregivers.
Study: NCT01650545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal aerosol cyclosporine
Description: inhaled form of immune suppression

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard immune suppression, oral
Description: conventional drug~Conventrional oral immune suppression as standard of care thus consists of tacrolimus, mycophenolate mofetil prednisone and rapamycin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard immune suppression, oral
Description: conventional drug~Conventrional oral immune suppression as standard of care thus consists of tacrolimus, mycophenolate mofetil prednisone and rapamycin
Study: NCT03838406

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: BRCA 1
Description: The investigators evaluated the incidence of BRCA loss in patients with advanced gastric cancer and observed the treatment outcome and prognosis.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BRCA 1
Description: The investigators evaluated the incidence of BRCA loss in patients with advanced gastric cancer and observed the treatment outcome and prognosis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days.
Study: NCT00876226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Citalopram pharmacokinetics will be studies in subjects with short bowel syndrome.~Citalopram 20mg orally will be given to the subjects and on the seventh day blood will be drawn at hours 0,1,2,3,4,6,8,12,16 and 24 hours post-dose.
Study: NCT04253405

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Catheter
Description: HFNC will be delivered through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.~Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize the patient´s comfort and SpO2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive positive pressure ventilation (NIPPV)
Description: NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 according to the protocol.
Study: NCT03650725

Intervention type: OTHER
Intervention: Mandatory Split bowel preparation
Description: Intervention describes the standard of care patient split bowel preparation instructions as mandatory, instead of giving patient instructions with option of choice between split or day before bowel prep.
Study: NCT03279796

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived MSCs
Description: The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 \^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound betamethasone
Description: 1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.
Study: NCT03201874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain self-management
Description: The program is designed to enhance self-efficacy. The app will guide youth in setting structured and personalized goals aimed at improving their pain and functioning. The pain self-management skills will include personalized CBT-based coping skills including deep breathing, relaxation, and cognitive skills (e.g., staying positive). The app will provide in-the-moment access to pain coping strategies to promote positive changes in mood, behavior, and pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education about sickle cell disease to increase disease knowledge

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Education about sickle cell disease to increase disease knowledge
Study: NCT00777322

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excimer laser ablation, and collagen cross-linking
Description: Surgery is performed with topical anaesthesia. The central corneal epithelium is removed. Excimer laser ablation is applied (typically 15-30 seconds). Residual bed thickness is checked with an ultrasonic pachymeter. Topical application of riboflavin 0.1% in dextran is commenced at 5 minute intervals. When an adequate saturation of the anterior chamber with riboflavin has been achieved, cross-linking treatment will proceed. Output from the UV light generating equipment is measured with a UV light meter and set at 3mW/cm². Thirty minutes of treatment is given, interrupted at five minute intervals by the application of more topical riboflavin drops. Finally the eye has a bandage soft contact lens placed, with preservative free topical antibiotic, steroid, and cycloplegic drop application.
Study: NCT01647919

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cogniVida™ 100 mg/day
Description: 4 capsules 25 mg (total 100 mg) cogniVida™ once a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules of placebo identical to cogniVida™ once a day
Study: NCT00480493

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STEP
Description: Experimental: Minutes of parent mentor-parent participant interactions Control: Minutes of parent contact-parent participant interactions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEP
Description: Experimental: Minutes of parent mentor-parent participant interactions Control: Minutes of parent contact-parent participant interactions
Study: NCT01131884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamax
Description: 70mg of Bisphosphonate therapy (Fosamax) will be taken weekly for a year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is an inactive pill that will look similar to the active drug. You will not know whether you are receiving active drug or placebo.
Study: NCT03769675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Spinal Cord Stimulator
Description: The SCS implant will follow standard clinical practice for these FDA approved indications. Two percutaneous leads will be placed in the posterior spinal epidural space under radiographic guidance and attached to either an external stimulator (trial phase) or a subcutaneously implanted impulse generator (IPG). Intraoperative impedance testing will be performed to ensure electrical integrity. Patients with HF10 SCS will receive 30 µs pulses delivered at 10,000 Hz with amplitude adjusted to optimal analgesic response. Programming will occur postoperatively and as needed based on patient feedback in standard clinic visits. .
Study: NCT02613429

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: identification of the airway by from the cranial end
Description: The airway is identified with inspection and imaging technique (ultrasound) by placing the ultrasound transducer over the thyroid cartilage and from there moving distally

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: identification of the airway from the distal end
Description: The airway is identified with inspection and imaging technique (ultrasound) by placing the ultrasound transducer over the distal trachea and moving cranially
Study: NCT00550771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin, cyclophosphamide, paclitaxel, trastuzumab
Description: doxorubicin 60 mg/m\^2 IV push + cyclophosphamide 600 mg/m\^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m\^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD, cyclophosphamide, trastuzumab, paclitaxel
Description: PLD 35 mg/m\^2 IV over 60 minutes + cyclophosphamide 600 mg/m\^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m\^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)
Study: NCT00535795

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation Therapy
Study: NCT04201717

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic assisted left colectomy
Description: All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion. The patients in the control group underwent with the traditional laparoscopic assisted technology. The free colon was taken out through a small incision in the middle of the abdomen or the outer edge of the left rectus abdominis. The mesentery was trimmed, the specimens were removed, and the anastomosis was completed. After the anastomosis, the whole surgical area was flushed and drainage tubes were left.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total laparoscopic left colectomy
Description: All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion. In the experimental group, the mesentery was endoscopically trimmed, the specimens were excised and the anastomosis was completed under the laparoscope. The specimens were taken out through trocar incision in the navel or in the right lower abdomen. After the anastomosis, all surgical area was flushed and drainage tubes were left.
Study: NCT02921152

Intervention type: PROCEDURE
Group type: OTHER
Intervention: bone marrow aspiration /trephine biopsy
Study: NCT02335398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: The starting methadone dose for naïve-opioid patients was 2.5-5 mg every 8-12 hours. In patients who required opioid rotation, the conversion ratios, morphine:methadone, were 4:1, 8:1, and 12:1 for patients receiving less than 90 mg of morphine, receiving 90-300 mg of morphine, and receiving more than 300 mg of morphine , respectively. A fixed dose ratio of 1:20 was applied for changing from transdermal fentanyl to oral methadone. Then, the daily calculated methadone dose was divided into 8-12 hourly dosing. Calculated rescue dose was estimated to be 10-15% of total daily dose of methadone which there was switched to be morphine syrup in the ratio of 1:4.
Study: NCT01742949

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated humidification (ThermoSmart)
Description: Heated Humidification (ThermoSmart) Turned On

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: No Humidification
Description: Heated Humidification (ThermoSmart) Turn Off
Study: NCT02505334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Injected subcutaneously s.c. (under the skin) once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Injected subcutaneously s.c. (under the skin) once daily.
Study: NCT02303847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ultra-low dose oral ketamine twice daily in two different doses over a 2 week period.
Study: NCT00476892

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pelvic Floor Muscle Training
Description: Women in the intervention group attend 5 physiotherapy sessions. At each appointment a clinical history is taken, pelvic floor muscle assessment carried out, exercises taught and prescribed, and appropriate lifestyle advice given. At the first of these appointments a detailed explanation of the pelvic anatomy and different types of prolapse is given.
Study: NCT00888602

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3.4 g psyllium
Description: 3.4 g psyllium served with meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 6.8 g psyllium
Description: 6.8 g psyllium served with a meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 6.8 g psyllium
Description: 6.8 g psyllium

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Meal
Description: meal
Study: NCT00091637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexelizumab
Description: Pexelizumab (2 mg/kg) intravenous , bolus for 10 minutes once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: bolus infusion over a 10 minute period once
Study: NCT00274443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007 (Abraxane) and Carboplatin
Description: ABI-007 plus Carboplatin will be administered intravenously over 30 minutes in cycles of 3 weeks
Study: NCT06073275

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice ingestion
Description: Beetroot juice ingestion was randomly administered 3 h before the start of the test to the participants in two assessment sessions with a one-week washout between both sessions.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ingestion
Description: Placebo ingestion was randomly administered 3 h before the start of the test to the participants in two assessment sessions with a one-week washout between both sessions.
Study: NCT03589963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postnatal Lactation Support
Description: In-home breastfeeding support delivered by professional lactation consultants and provision of a high-quality breast pump
Study: NCT03594019

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Connective tissue graft
Description: Connective tissue graft (CTG) is an oral and maxillofacial surgical procedure first described by Alan Edel in 1974. It includes the preparation the recipient site of tissue exhibiting recession by incising the gingival, obtaining the CTG from the donor site, securing the CTG at the recipient site and suturing the incised gingival tissue at both the donor and recipient sites.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: socket shield technique
Description: The procedure is used to split the teeth and preserve the buccal part

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Immediate implant placement
Description: The implant will be placed in the frest socket immediately after tooth extraction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implant placement
Description: The implant will be placed in the frest socket immediately after tooth extraction
Study: NCT02342548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg BID of PF-02545920
Description: All subject who completed A8241021 will receive 20 mg BID (with or without titration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg BID of PF-02545920
Description: All subject who completed A8241021 will receive 20 mg BID (with or without titration)
Study: NCT04486170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education provided via a video format
Description: The intervention group will be shown a 5 minute educational video on hypertension in the postpartum period. The patients will be shown the video on the ipad while they are in the comfort of their room and the investigator will step outside. At the conclusion of the video, the investigator will return into the patient room and provide a pamphlet with similar information that was discussed in the video for them to take home.
Study: NCT02063048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Based Weight Loss Support